AbbVie Trims 2024 Profit Outlook Amid $1.6 Billion Acquisition Costs
2025-01-06Reuters
Pharmaceutical giant AbbVie has revised its 2024 adjusted profit forecast downward due to significant acquisition expenses. The company incurred a substantial $1.6 billion in costs, primarily related to milestone payments and research-and-development ...Read more
